Gil Blum
Analyst
Needham & Company
Equibles does not estimate personal net worth.
About Gil Blum
Gil Blum is recorded as Analyst at Needham & Company. Gil Blum has spoken on 6 earnings calls and 2 other investor events across 7 companies, most recently for Faeth Therapeutics, Inc. on April 16, 2026. Those appearances were for Cartesian Therapeutics, Inc. (RNAC), Faeth Therapeutics, Inc. (FTH), Autolus Therapeutics plc (AUTL), Celcuity Inc. (CELC), Absci Corp (ABSI) and 2 other companies. The companies whose calls Gil Blum spoke on are classified in the Healthcare sector.
Gil Blum on recent calls
“Good afternoon, everyone, and thank you for joining us on the fourth day of the Needham Health Care Conference. My name is Gil Blum, and I'm a senior biotech analyst here at Needham & Company.”
“It is my pleasure to have with me today, Carson Brun, the CEO of Cartesian. As a reminder, any viewers who are watching through our conference portal are able to submit questions via the Ask a Question box below the video feed window.”
“Do you think this is going to influence physician behavior? Is this sufficiently socialized? I mean, feedback that we've gotten is most physicians already view Ocatel as a preferred therapeutic.”
“So, a commercial question that we've gotten a couple of times is surrounding potential challenges in getting patients to come in for infusions.”
“The line is open. in, and thanks for taking our questions. Maybe a bit of a math question. You said three cohorts were a dose. Should we assume this is about 24 patients at this point?”
Affiliation history
-
Needham & Company
Analyst
Source not stated
Current
Company network
Celcuity Inc.
CELC
Biotechnology · Healthcare
1 appearance
Latest appearance 2026-03-25
View calls and events
Absci Corp
ABSI
Biotechnology · Healthcare
1 appearance
Latest appearance 2026-03-24
View calls and events
Geron Corp
GERN
Biotechnology · Healthcare
1 appearance
Latest appearance 2026-02-25
View calls and events